Pharmacological Research - Modern Chinese Medicine最新文献

{"title":"Gas chromatography–mass spectrometry (GC–MS) analysis and high-performance thin-layer chromatography (HPTLC) fingerprinting profile of petroleum ether extract of Laurus nobilis Linn. (Yue Gui Ye) leaves","authors":"Aishwarya R. Chavan , Omkar S. Ghatge , Roshan R. Kamble , Manish S. Kondawar","doi":"10.1016/j.prmcm.2025.100728","DOIUrl":"10.1016/j.prmcm.2025.100728","url":null,"abstract":"<div><h3>Background</h3><div><em>Laurus nobilis Linn. (Lauraceae),</em> commonly known as Bay Laurel and referred to as Yue Gui Ye in Traditional Chinese Medicine (TCM), has been used for centuries as a culinary spice and a therapeutic herb. It is reputed for its carminative, antiseptic, and anti-inflammatory actions and for promoting digestion and circulation of Qi. Despite widespread usage, the systematic chemical profiling of its non-polar (petroleum ether) extracts remains limited, which constrains standardization efforts and pharmacological validation. Previous studies have largely focused on essential oils obtained by steam distillation, leaving a knowledge gap regarding semi-volatile components uniquely extractable in petroleum ether.</div></div><div><h3>Objective</h3><div>To establish chromatographic fingerprints and to identify major volatile and semi-volatile compounds in the petroleum ether extract of L. nobilis leaves, thereby supporting its quality control and ethnopharmacological relevance. Additionally, to compare the detected compounds with previous literature to identify newly reported and previously confirmed phytoconstituents.</div></div><div><h3>Methods</h3><div>Fresh L. nobilis leaves were collected, authenticated, and extracted using petroleum ether (40–60°C) via Soxhlet apparatus. The extract was analyzed by HPTLC using silica gel 60 F₂₅₄ plates and scanned at 366 nm, and by GC–MS using a Shimadzu TQ-8050 HS20 system. Compounds were identified using NIST 2020 library data. Literature between 2010–2024 was systematically reviewed using PubMed, Scopus, and Google Scholar to determine the novelty or previously reported nature of each compound.</div></div><div><h3>Results</h3><div>The HPTLC fingerprint displayed eight major peaks, confirming chemical diversity. GC–MS analysis identified twenty-nine volatile compounds dominated by α-pinene (32.38%), o-cymene (20.06%), γ-terpinene (9.83%), and β-myrcene (7.94%). Comparison with earlier studies revealed that key monoterpenes including α-pinene, β-myrcene, limonene, linalool, and γ-terpinene have been consistently reported in essential oils and organic extracts. However, six detected semi-volatile compounds (tetradecane, hexadecane, pentadecene isomer, benzaldehyde derivative, phytol acetate, and a minor sesquiterpene oxide) appear newly reported for petroleum ether extracts, indicating chemotype broadening beyond essential-oil profiles. Replicate analysis showed less than 2% RSD, confirming analytical consistency.</div></div><div><h3>Conclusion</h3><div>A chemical fingerprint of Yue Gui Ye was established using GC–MS and HPTLC. The findings confirm the predominance of α-pinene and o-cymene reported extensively in earlier literature, while also highlighting several newly detected constituents unique to petroleum ether extraction. This comparative profiling enhances the understanding of L. nobilis phytochemical diversity and provides reference data for herbal standardization in Trad","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"17 ","pages":"Article 100728"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145693358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoralen from Ficus carica: Fractionation, bioactivity, and toxicological-pharmacokinetic comparison with silymarin","authors":"Kiren Mustafa ,&nbsp;Noreen Akhtar ,&nbsp;Hina Khalid ,&nbsp;Madiha Younas ,&nbsp;Muhammad Tariq Saeed ,&nbsp;Yuanda Song ,&nbsp;Zhihe Li ,&nbsp;Hassan Mohamed","doi":"10.1016/j.prmcm.2025.100690","DOIUrl":"10.1016/j.prmcm.2025.100690","url":null,"abstract":"<div><h3>Background</h3><div><em>Ficus carica</em> (无花果 <em>wúhuāguǒ</em>) is valued in traditional Chinese medicine (TCM) and nutrition for its rich phytochemical content. Our prior research showed a crude fig extract (FLA) selectively fought liver cancer cells (HepG2) in vitro while sparing normal cells.</div></div><div><h3>Purpose</h3><div>We aimed to isolate an active compound from FLA and analyze the potent bioactivities, particularly anticancer potential, through in vitro and computational studies.</div></div><div><h3>Method</h3><div>An innovative strategy combined fractionation by vacuum liquid chromatography (VLC) on silica gel (using six non-polar to polar solvent gradients) with thin layer chromatography (TLC) and bioactivity screening on liver (HepG2) and gastric (SGC-7901) cancer cell lines, and antimicrobial assay. The active Fraction 2 (Fr-2) was repeatedly sub-fractionated using Sephadex LH-20 column chromatography and TLC to isolate psoralen. Its mechanism of action against key cancer markers was evaluated via RT-qPCR, molecular docking, and ADMET pharmacokinetic analysis, with silymarin as a comparator.</div></div><div><h3>Results</h3><div>Fractionation of FLA yielded Fr- 2 (Hexane: Ethyl acetate, 50:50) with the IC50 (mg/mL) against HepG2 (0.31 ± 0.1) and SGC-7901 (0.124 ± 0.05) among the six tested fractions. It also exhibited antimicrobial activity, showing maximum inhibition zones (mm) against <em>Aspergillus flavus</em> FL (18± 0.4 mm), <em>Penicillium chrysogenum</em> FL (20 ± 0.7 mm), and <em>Pseudomonas aeruginosa</em> (17 ± 0.8 mm). Sub-fractionation of Fr- 2 led to the identification of psoralen, which decreased the genetic expression of tumor suppressor Tp53, anti-apoptotic (Bcl2) and Cell cycle kinases (CDK1 and CDK5). Molecular interaction via molecular docking against critical cancer regulators: Tp53, oncoproteins MDM2 and Bcl2, and CDK1/CDK5 also revealed the strong binding affinity of Psoralen. Psoralen demonstrates a novel mechanism of action by dual targeting of the MDM2-p53 axis: it binds p53′s N-TAD (Arg23, -8.8 kcal/mol) to reduce ubiquitination, while competitively inhibiting MDM2 (-5.8 kcal/mol) to stabilize Tp53 and induce apoptosis. Comparative ADMET analysis revealed psoralen's superior water solubility and oral bioavailability (96.67 % absorption) versus silymarin.</div></div><div><h3>Conclusion</h3><div>The active Fr-2, featuring psoralen, demonstrates broad antimicrobial and anticancer activity by potentially inhibiting the MDM2-p53 pathway to induce apoptosis, and it exhibits a superior ADMET profile compared to silymarin.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"17 ","pages":"Article 100690"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145107938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laiyang pear cough syrup relieves cough through the PI3K-AKT pathway","authors":"Haoling Liu ,&nbsp;Yiying Zhao ,&nbsp;Yige Zhao ,&nbsp;Kairui Gao ,&nbsp;Yawen Xue ,&nbsp;Dongyue Ma ,&nbsp;Jia Liu ,&nbsp;Zhenquan Liu ,&nbsp;Wenyan Sun","doi":"10.1016/j.prmcm.2025.100702","DOIUrl":"10.1016/j.prmcm.2025.100702","url":null,"abstract":"<div><h3>Objective</h3><div>To predict the mechanism of action of Laiyang Pear Cough Syrup in treating cough by using network pharmacology, molecular docking technology and the predicted key pathways in animal experiments.</div></div><div><h3>Methods</h3><div>Chemical components of each medicinal flavor were collected and screened from TCMSP and other databases to establish a database of the components of Laiyang Pear Cough Syrup. Cough-related targets were obtained from TTD and other databases. A Venn diagram of the components targets and cough targets was drawn to prelim determine the potential targets of the active ingredients of Laiyang Pear Cough Syrup in the treatment of cough. A PPI network was constructed and key targets were screened. The data were into Cytoscape 3.10.1 software, and a \"active component-disease target\" network was constructed, and key components were screened. The screened targets were subjected to GO enrichment analysis and KEGG pathway enrichment analysis. Molecular docking verification between key targets and core active ingredients was conducted using AutoDock Tools 1.5.6 software. A citric acid-induced guinea pig cough model was established. The cough latency and cough frequency were measured in the control and treatment groups, and the PI3K-AKT pathway predicted by network pharmacology was validated via Western blot analysis.</div></div><div><h3>Results</h3><div>43 active chemical components, 76 common targets, 591 GO biological processes, and 159 KEGG signaling pathways were screened out. The active components of Laiyang Pear Cough Syrup in the treatment of cough may be quercetin, stigmasterol, and luteolin, and the key may be IL-6, TNF, AKT1, IL-1β, and PTGS₂, which mainly regulate the PI3K/AKT pathway to relieve cough. Molecular docking revealed that luteolin, quercetin, and stigmasterol as the key active ingredients in Laiyang Pear Cough Syrup bind to AKT1 with high affinities, displaying docking scores of −8.1, −8.0, and −7.7 kcal mol⁻¹. These results indicate that the compounds may function as potent agonists to activate the PI3K-AKT signaling pathway. Laiyang Pear Cough Syrup can significantly prolong the cough latency period and reduce the number of coughs (compared with the control group, <em>P</em> &lt; 0.01 or 0.05), and down-regulate the expression of PI3K, p-PI3K, AKT, p-AKT proteins.</div></div><div><h3>Conclusion</h3><div>Laiyang Pear Cough Syrup can relieve cough through a variety of components, targets and pathways. Regulating the PI3K-AKT pathway may be its main mechanism of action.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"17 ","pages":"Article 100702"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145321065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herb-drug interactions involving pueraria lobata and its bioactive constituents: A comprehensive review","authors":"Chenggong Xie ,&nbsp;Chujiong Chen ,&nbsp;Zelin Ke ,&nbsp;Hengyu Tan ,&nbsp;Hongze Zhao ,&nbsp;Xuxiang Deng ,&nbsp;Hao Liang ,&nbsp;Yidi Zeng","doi":"10.1016/j.prmcm.2025.100696","DOIUrl":"10.1016/j.prmcm.2025.100696","url":null,"abstract":"<div><h3>INTRODUCTION</h3><div>Pueraria lobata (PL) is a traditional Chinese medicinal herb that is rich in isoflavonoids, such as puerarin and daidzein. It is widely used to treat cardiovascular, metabolic and oncological disorders. As PL is increasingly being co-administered with conventional drugs, herb–drug interactions (HDI) have emerged as a significant clinical concern. A comprehensive synthesis of the current evidence base is required to clarify the pharmacodynamic and pharmacokinetic profiles of PL-related interactions, as well as their implications for clinical practice.</div></div><div><h3>METHODS</h3><div>We conducted a comprehensive review of experimental and clinical studies on HDI involving PL and its bioactive constituents. Literature was retrieved from PubMed, CNKI, and Google Scholar up to April 2024. Studies were included if they reported on the pharmacodynamic or pharmacokinetic interactions between PL (or its constituents) and therapeutic drugs. Twenty-three studies met the eligibility criteria: Twelve addressed pharmacodynamic interactions and eleven addressed pharmacokinetic interactions.</div></div><div><h3>RESULTS</h3><div>In terms of pharmacodynamics, PL exhibited both synergistic and antagonistic effects. Synergistic outcomes included enhanced efficacy in terms of cardiovascular protection, osteoporosis prevention, glycaemic control and chemosensitisation in cancer therapy. Conversely, adverse outcomes were observed, including attenuation of the antiplatelet effect when combined with warfarin or dual antiplatelet therapy and increased mortality when combined with methotrexate in animal models. In terms of pharmacokinetics, puerarin and other constituents were found to modulate cytochrome P450 enzymes and transporters. The effects included inhibiting CYP2D6, suppressing CYP3A, inducing CYP1A2 and altering P-glycoprotein activity. These mechanisms contribute to variable drug metabolism and bioavailability across co-administered agents.</div></div><div><h3>DISCUSSION</h3><div>Evidence suggests that PL can have beneficial or harmful effects on HDI, depending on the therapeutic context. However, the available data is limited and is largely derived from preclinical models. There is a lack of rigorous clinical trials and the roles of minor constituents remain under-explored. Research gaps include a lack of data on high-risk populations and an incomplete understanding of the mechanisms of pharmacodynamic interactions. To ensure the rational and safe integration of PL into modern medical practice, future work should prioritise translational studies and broaden the focus beyond puerarin to establish safety profiles.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"17 ","pages":"Article 100696"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145221977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qingyi decoction modulates fibrotic pathways in severe acute pancreatitis: A histological and molecular study","authors":"Shayan Chen ,&nbsp;Zhihuang Wu ,&nbsp;Wendie Yu ,&nbsp;Di Zou ,&nbsp;Jiongtang Lu","doi":"10.1016/j.prmcm.2025.100684","DOIUrl":"10.1016/j.prmcm.2025.100684","url":null,"abstract":"<div><h3>Background</h3><div>Qingyi Decoction (QYD), a traditional Chinese medicine (TCM) formulation derived from Dachaihu Decoction, is used to treat severe acute pancreatitis (SAP). While QYD's components, <em>rhubarb</em> and <em>bupleurum</em>, possess known anti-fibrotic properties, their mechanisms in SAP remain unclear. This study investigated QYD's anti-fibrotic effects and underlying mechanisms in a lipopolysaccharide (LPS)- and cerulein-induced mouse model of SAP.</div></div><div><h3>Methods</h3><div>SAP was induced in mice by intraperitoneal injection of cerulein and LPS. The QYD+SAP group received oral administration of QYD at twice the clinical dosage. Following modeling and QYD treatment, pancreatic tissues were harvested for examination of fibrotic parameters using histological methods. Additionally, the anti-fibrogenic effects of QYD on pancreatic tissue were investigated using Western blotting and laser scanning confocal microscopy.</div></div><div><h3>Results</h3><div>In SAP mice, histological examination of pancreatic tissues revealed significant tissue damage. However, QYD treatment ameliorated the histological severity of SAP. Furthermore, QYD decreased the expression of pancreatic fibrosis and PSC activation markers, including α-SMA, collagen, and fibronectin, while enhancing pancreatic acinar cell survival and restoring exocrine pancreatic function. Mechanistically, QYD treatment inhibited the activation of JNK, ERK, and p38 MAPK pathways, as well as prevented IκBα degradation in pancreatic tissues.</div></div><div><h3>Conclusion</h3><div>This study demonstrates the presence of mild pancreatic fibrosis in SAP and reveals QYD's anti-fibrotic effects through the inhibition of JNK, ERK, and p38 MAPK signaling pathways and the prevention of IκBα degradation.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"17 ","pages":"Article 100684"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145107939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to “Enhancements of Bcl-2/mTOR/ERK1/2 activities by antioxidant mechanisms confer cardioprotection on Ginkgo biloba supplement against isoprenaline-induced myocardial infarction in rats” [Pharmacological Research – Modern Chinese Medicine 8 (2023) 100293]","authors":"Jerome Ndudi Asiwe ,&nbsp;Benneth Ben-Azu ,&nbsp;Godwin D. Yovwin ,&nbsp;Santos Ehizokhale Ehebha ,&nbsp;Vincent-Junior Onoriode Igben ,&nbsp;Endurance Efe Ahama ,&nbsp;Akpevwoghene Agbatutu ,&nbsp;Tarela Melish Elias Daubry ,&nbsp;Benjamin Oritsemuelebi ,&nbsp;Emuesiri Goodies Moke","doi":"10.1016/j.prmcm.2025.100705","DOIUrl":"10.1016/j.prmcm.2025.100705","url":null,"abstract":"","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"17 ","pages":"Article 100705"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145733345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Honokiol as a next-generation phytotherapeutic: Anticancer, neuroprotective, and nanomedicine perspectives","authors":"Dilpreet Singh ,&nbsp;Nandni ,&nbsp;Neena Bedi","doi":"10.1016/j.prmcm.2025.100713","DOIUrl":"10.1016/j.prmcm.2025.100713","url":null,"abstract":"<div><h3>Introduction</h3><div>Honokiol (<strong>厚朴酚, Hou Po Fen</strong>), a biphenolic compound derived from the bark of <em>Magnolia officinalis</em> (<strong>厚朴, Hou Po</strong>), has emerged as a promising phytochemical with multi-target pharmacological activities. Traditionally used in East Asian medicine, it is now being investigated for applications in cancer, neurodegenerative disorders, inflammation, and infectious diseases. Its therapeutic promise is attributed to its ability to modulate critical signaling pathways including NF-κB, STAT3, PI3K/Akt/mTOR, and Nrf2.</div></div><div><h3>Methods</h3><div>This review synthesizes and critically analyzes published evidence on honokiol’s chemical properties, mechanisms of action, pharmacological activities, and nanotechnology-based delivery systems. Literature was sourced from PubMed, Scopus, and Web of Science databases, focusing on preclinical, clinical, and formulation studies of honokiol between 2000–2025. Key molecular targets, in vitro and in vivo efficacy, and translational challenges were evaluated and summarized.</div></div><div><h3>Results</h3><div>Honokiol demonstrates potent antioxidant, anti-inflammatory, anticancer, antimicrobial, and neuroprotective activities. It effectively induces apoptosis, inhibits angiogenesis, and modulates tumor microenvironmental factors. Neuroprotective actions include attenuation of neuroinflammation, preservation of mitochondrial function, and improvement of cognitive performance. Nanocarrier-based systems—such as liposomes, polymeric nanoparticles, micelles, and nanoemulsions—significantly improve honokiol’s solubility, stability, and bioavailability. Preclinical data confirm efficacy across cancer, neurological, and inflammatory models, though clinical evidence remains limited.</div></div><div><h3>Discussion</h3><div>Honokiol represents a promising next-generation phytotherapeutic candidate bridging traditional Chinese medicine and modern molecular pharmacology. Despite strong preclinical support, translational progress is hindered by low water solubility, poor bioavailability, limited clinical trials, and regulatory challenges. Advances in nanotechnology, epigenetic modulation, and personalized medicine approaches may accelerate clinical adoption. Future research should focus on standardized formulations, biomarker-driven trials, and integration with emerging therapeutic technologies.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"17 ","pages":"Article 100713"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145466289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polyphenolic-rich extract of Illicium verum fruit modulates inflammation in lipopolysaccharide-induced acute lung injury in rats","authors":"Maryam Adamu ,&nbsp;Olusola B. Adewale ,&nbsp;Scholastica O. Anadozie","doi":"10.1016/j.prmcm.2025.100717","DOIUrl":"10.1016/j.prmcm.2025.100717","url":null,"abstract":"<div><h3>Introduction</h3><div>Acute lung injury (ALI), one of the contributing factors of global mortality (about 40% of hospital deaths), is primarily associated with inflammatory responses and oxidative stress. <em>Illicium verum</em>, commonly called Ba jiao hui xiang <em>(八角茴香)</em> or Chinese star anise, is native to the subtropical provinces of Southwestern China and used in traditional Chinese medicine (TCM) to treat digestive disorders, insomnia, and colds, and as a spice in Chinese cuisines. This study investigated the protective effect of polyphenolic-rich extract of Illicium verum (PEIV) fruit against lipopolysaccharide (LPS)-induced ALI in rats.</div></div><div><h3>Methodology</h3><div>Phytochemicals in the plant was screened using high performance liquid chromatography (HPLC). Thirty-five male Wistar rats were grouped into seven as follows: Control, ALI (250 µg/kg LPS via intraperitoneal injection for 5 days), ALI + silymarin, ALI + PEIV (25, 50 and 100 mg/kg), and PEIV (100 mg/kg) via oral administration for 14 days. At the end of the experimental study, lung tissues were collected for biochemical (oxidative stress and pro-inflammatory (interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α)) and histological assays.</div></div><div><h3>Results</h3><div>Fourteen distinct biological compounds were identified by the HPLC analysis, with cinnamic acid being the most abundant, at a concentration of 58.99 µg/100 g. The LPS markedly (<em>p</em> &lt; 0.05) increased the tissue arginase activity and levels of malondialdehyde (MDA), TNF-α, and IL-6. Also, a significant (<em>p</em> &lt; 0.05) decrease was noted in the levels of nitric oxide (NO) and reduced glutathione (GSH), as well as the activities of enzymatic antioxidants (superoxide dismutase (SOD) and glutathione-s-transferase (GST)). However, pretreatment with PEIV protected the rats from LPS-induced ALI by a significant (<em>p</em> &lt; 0.05) reduction in the arginase activity and MDA levels and elevation (<em>p</em> &lt; 0.05) in the NO level and activities of antioxidant enzymes. Furthermore, PEIV reduced the levels of cytokines and reversed histological alterations induced by LPS.</div></div><div><h3>Conclusion</h3><div>The result of this study showed that PEIV protected the rats from LPS-induced ALI by suppressing oxidative stress and inflammation and, therefore, could be considered a promising anti-inflammatory agent in managing ALI.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"17 ","pages":"Article 100717"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145528410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of traditional Chinese medicine in combating metabolic disorders: A systematic review","authors":"Arpan Pathak ,&nbsp;Mohit Agrawal ,&nbsp;Pranshul Sethi ,&nbsp;Kantrol Kumar Sahu ,&nbsp;Monika Sharma ,&nbsp;Hema Chaudhary ,&nbsp;Devesh Kumar ,&nbsp;Thakur Gurjeet Singh ,&nbsp;Mohit Kumar","doi":"10.1016/j.prmcm.2025.100703","DOIUrl":"10.1016/j.prmcm.2025.100703","url":null,"abstract":"<div><h3>Introduction</h3><div>Metabolic disorders, including type 2 diabetes, obesity, hyperuricemia, and MASLD, are increasing worldwide, and conventional therapies often have limited efficacy. Traditional Chinese Medicine (TCM), with its multi-targeted approach, shows promise as a complementary strategy.</div></div><div><h3>Methods</h3><div>A systematic literature search was conducted in PubMed and CNKI (1966–2024) using predefined keywords related to TCM, metabolic disorders, clinical trials, and mechanisms. Eligible studies were screened and synthesized according to PRISMA guidelines to evaluate pharmacological pathways and therapeutic outcomes.</div></div><div><h3>Results</h3><div>Numerous TCM studies, including those on berberine, ginsenosides, bavachinin, and resveratrol, as well as formulations such as Shenge Formula, Huangqin Decoction, and Zibu Piyin Formula, have demonstrated the ability to regulate AMPK, PPARα, SIRT1, PI3K/Akt, and NF-κB signalling pathways. These interventions improve insulin resistance, lipid metabolism, inflammation, oxidative stress, and hepatic steatosis, with most findings derived from <em>in vitro and in vivo</em> studies.</div></div><div><h3>Conclusion</h3><div>TCM holds significant therapeutic potential for managing a spectrum of metabolic disorders through multi-target interventions that act on multiple interconnected biological systems. While preclinical and some clinical data support the efficacy and safety of TCM, further well-designed randomized clinical trials and integrated omics-based research are necessary to elucidate precise mechanisms, standardize formulations, and validate long-term outcomes. Integration of TCM into modern metabolic therapy may offer novel strategies for personalized and holistic healthcare.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"17 ","pages":"Article 100703"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145321496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"7,8-Dihydroxyflavone enhances the chemosensitivity of hepatocellular carcinoma cells to arsenic trioxide by disrupting mitochondrial oxidative phosphorylation","authors":"Dan-dan Guo ,&nbsp;Zhen Tian ,&nbsp;Ru-jin Liang ,&nbsp;Ting-ting Tan ,&nbsp;Yu-wei Hu ,&nbsp;Hua Zhu ,&nbsp;Jing Zhao ,&nbsp;Peng-zhou Hang","doi":"10.1016/j.prmcm.2025.100693","DOIUrl":"10.1016/j.prmcm.2025.100693","url":null,"abstract":"<div><h3>Introduction</h3><div>Arsenic trioxide (ATO) has a well-documented history in traditional Chinese medicine as an effective treatment for acute promyelocytic leukemia and certain solid tumors; however, its efficacy as a standalone chemotherapy agent is limited. 7,8-Dihydroxyflavone (DHF), a TrkB receptor agonist, has shown promising anticancer effects across various malignancies. This study aimed to investigate the therapeutic potential of DHF, both alone and in combination with ATO, in hepatocellular carcinoma (HCC) cells.</div></div><div><h3>Methods</h3><div>The HCCLM3 and HepG2 cell lines were treated with ATO and DHF, alone or in combination. Cell viability and death ratio were assessed using MTT and live/dead staining. Proliferation and migration were evaluated through EdU staining, wound-healing assays, and colony formation assays. Apoptosis was detected via TUNEL staining, while changes in morphology and mitochondrial function were assessed using Mito-Tracker, transmission electron microscopy, mito-SOX, and JC-1 staining.</div></div><div><h3>Results</h3><div>The combination of DHF and ATO significantly reduced cell viability, proliferation, and migration, while concurrently increasing cell death and apoptosis compared to monotherapy. Mechanistically, combination treatment notably decreased mitochondrial membrane potential, increased the production of mitochondrial reactive oxygen species (ROS), and suppressed mitochondrial respiration, which was accompanied by reduced protein levels of mitochondrial complexes I, II, III, and V. Furthermore, these effects were reversed by the mitochondrial uncoupler CCCP at a low dose.</div></div><div><h3>Conclusion</h3><div>These findings suggest that the DHF-ATO combination suppresses HCC progression by impairing mitochondrial oxidative phosphorylation, providing a promising strategy to enhance chemotherapeutic efficacy.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"17 ","pages":"Article 100693"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145160136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}